THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM
See full prescribing information for complete boxed warning.
- TRADE NAME: Hemlibra (Genentech)
- INDICATIONS: Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors
- CLASS: Factor IXa- and factor X-directed antibody, Monoclonal antibody
- HALF-LIFE: ~30 days
- FDA APPROVAL DATE: 11/16/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No available data to inform drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of emicizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 10/12/2023
